JP2025501372A5 - - Google Patents
Info
- Publication number
- JP2025501372A5 JP2025501372A5 JP2024541042A JP2024541042A JP2025501372A5 JP 2025501372 A5 JP2025501372 A5 JP 2025501372A5 JP 2024541042 A JP2024541042 A JP 2024541042A JP 2024541042 A JP2024541042 A JP 2024541042A JP 2025501372 A5 JP2025501372 A5 JP 2025501372A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/070870 | 2022-01-09 | ||
| CN2022070870 | 2022-01-09 | ||
| CN2022117334 | 2022-09-06 | ||
| CNPCT/CN2022/117334 | 2022-09-06 | ||
| PCT/CN2023/071334 WO2023131329A1 (en) | 2022-01-09 | 2023-01-09 | Multispecific constructs and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501372A JP2025501372A (ja) | 2025-01-17 |
| JP2025501372A5 true JP2025501372A5 (enExample) | 2025-11-27 |
Family
ID=87073282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024541042A Pending JP2025501372A (ja) | 2022-01-09 | 2023-01-09 | 多重特異性構築物及びその方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250074995A1 (enExample) |
| EP (1) | EP4460527A4 (enExample) |
| JP (1) | JP2025501372A (enExample) |
| KR (1) | KR20240133746A (enExample) |
| CN (1) | CN119173539A (enExample) |
| AU (1) | AU2023205989A1 (enExample) |
| CA (1) | CA3248088A1 (enExample) |
| MX (1) | MX2024008500A (enExample) |
| WO (1) | WO2023131329A1 (enExample) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| US11739136B2 (en) * | 2019-03-18 | 2023-08-29 | Innovative Cellular Therapeutics Holdings, Ltd. | Inducible dominant negative PD-1 and uses in adoptive cell therapy |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| PH12022552323A1 (en) * | 2020-03-31 | 2023-12-04 | Chugai Pharmaceutical Co Ltd | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof |
| EP4138864A4 (en) * | 2020-04-23 | 2024-07-10 | Innovative Cellular Therapeutics Holdings, Ltd. | Polyspecific binding molecules and their use in cell therapy |
| WO2021247474A1 (en) * | 2020-06-02 | 2021-12-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Sstr-binding chimeric antigen receptors |
| CN117355540A (zh) * | 2021-05-21 | 2024-01-05 | 百济神州有限公司 | 抗cd137抗体和使用方法 |
| CA3230426A1 (en) * | 2021-09-03 | 2023-03-09 | Novarock Biotherapeutics, Ltd. | Bispecific binding proteins that bind cd137 and a tumor associated antigen |
-
2023
- 2023-01-09 MX MX2024008500A patent/MX2024008500A/es unknown
- 2023-01-09 CA CA3248088A patent/CA3248088A1/en active Pending
- 2023-01-09 CN CN202380024591.3A patent/CN119173539A/zh active Pending
- 2023-01-09 EP EP23737191.9A patent/EP4460527A4/en active Pending
- 2023-01-09 WO PCT/CN2023/071334 patent/WO2023131329A1/en not_active Ceased
- 2023-01-09 KR KR1020247026895A patent/KR20240133746A/ko active Pending
- 2023-01-09 US US18/727,561 patent/US20250074995A1/en active Pending
- 2023-01-09 JP JP2024541042A patent/JP2025501372A/ja active Pending
- 2023-01-09 AU AU2023205989A patent/AU2023205989A1/en active Pending